Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Device Attribute Testing

    October 6, 2017 | Blood glucose monitoring, Case study, Device testing, Healthcare Market Research, conjoint 

    Our client wanted to determine the optimal new blood glucose monitoring device – one that would best retain their current customers and also attract new ones.  They also wanted to be able to rationalise the strengths of their existing portfolio against their competitors. The patient evaluation needed to reflect real life as much as possible, so that it truly reflected patient preference and could predict the future market impact of any new device.

    Read the full case study: https://www.researchpartnership.com/news/2017/09/device-attribute-testing/

    This content was provided by Inizio

    Company Details

    - PMLiVE

    Inizio

    Email
    Website

     Latest Content from  Inizio 

    Delivering purposeful solutions at Obesity Week 2025

    We’re attending Obesity Week 2025, the world’s leading event dedicated to obesity research and care, to showcase how our integrated expertise is advancing progress in obesity and cardiometabolic health.

    Inizio strengthens executive team with new leadership appointments

    Inizio has appointed Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer, strengthening its executive leadership to drive innovation, digital transformation, and Intelligent Commercialization™...

    Inizio celebrates six finalist honors at the 2025 PM360 Trailblazer Awards

    Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across...

    Inizio leaders featured in Forbes’ ‘Voices of Oncology’ to drive innovation in cancer care

    Inizio experts contribute to Forbes’ Voices of Oncology, highlighting our commitment to driving innovation in cancer care through advanced data analytics, cross-sector collaboration, and real-world impact for patients.

    Inizio appoints Ryan Quigley as CEO

    Inizio have appointed Ryan Quigley as Chief Executive Officer, effective 9 September 2025. Paul Taaffe will remain closely involved with the company as an Advisor and board member going forward. ...

    What oncologists really want from booth strategy

    Simon Davenport, Global Head of Environments, Emota, an Inizio Engage company  At this year’s ASCO® congress, the spotlight wasn’t just on science – it was on how the industry engages. Supporting over 30...

    How smart spaces and real-time strategy transformed ASCO® 2025

    Nick Bellomo, Director of Technology and Engagement, Inizio Medical ASCO® 2025 wasn’t just about oncology breakthroughs - it was also a showcase for how technology is redefining congress engagement. Supporting...

    The science is shifting in oncology: Are you ready to evolve with it?

    Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke. This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic...

    Reimagine health with Inizio.

    At Inizio, we provide tailored, innovative solutions to help health and life sciences companies with their clinical development and commercialization journeys, maximizing patient access. Our experts guide you through each...

    Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development

    Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...